Ph3 study of T-DXd in patients with HER2-expressing endometrial cancer
Phase III Clinical Trial
DESTINY-Endometrial 01: An Open-Label Sponsor-Blinded Randomized Controlled Multicenter Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as FirstLine Therapy of HER2-Expressing (IHC 3+/2+) Mismatch Repair Proficient (pMMR) Primary Advanced or Recurrent Endometrial Cancer. (D781DC00001)